Boris Pasche: FDA has approved the TheraBionic P1 device for advanced hepatocellular carcinoma
Boris Pasche, President and CEO of the Karmanos Cancer Institute, shared a post on LinkedIn:
“Exciting news for individuals with advanced hepatocellular carcinoma! The FDA has approved the TheraBionic P1 device, providing a new treatment option for patients who have not responded to previous therapies. The device is accessible to patients as of December 2024.
Stay informed about this groundbreaking development by visiting.”
More posts featuring Boris Pasche.
Boris Pasche is the President and CEO of the Karmanos Cancer Institute and Chair of the Department of Oncology at Wayne State University. He is a co-founder and member of TheraBionic Inc. and focuses on enhancing patient outcomes through innovative therapeutic technologies and comprehensive cancer management strategies.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023